Andexanet alfa versus four-factor prothrombin complex concentrate for the reversal of apixaban- or rivaroxaban-associated intracranial hemorrhage: a propensity score-overlap weighted analysis

BACKGROUND: Andexanet alfa is approved (FDA “accelerated approval”; EMA “conditional approval”) as the first specific reversal agent for factor Xa (FXa) inhibitor-associated uncontrolled or life-threatening bleeding. Four-factor prothrombin complex concentrates (4F-PCC) are commonly used as an off-l...

Descripción completa

Detalles Bibliográficos
Autores principales: Costa, Olivia S., Connolly, Stuart J., Sharma, Mukul, Beyer-Westendorf, Jan, Christoph, Mary J., Lovelace, Belinda, Coleman, Craig I.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9204964/
https://www.ncbi.nlm.nih.gov/pubmed/35710578
http://dx.doi.org/10.1186/s13054-022-04043-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9204964/
https://www.ncbi.nlm.nih.gov/pubmed/35710578
http://dx.doi.org/10.1186/s13054-022-04043-8

Ejemplares similares